- Home
- GBR vs DCOY Comparison
GBR vs DCOY Comparison
Compare GBR & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | DCOY |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.2M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | GBR | DCOY |
|---|---|---|
| Price | $0.68 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 40.9K | 32.9K |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.62 | $0.53 |
| 52 Week High | $1.31 | $13.51 |
Technical Indicators
Market Signals| Indicator | GBR | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 37.90 |
| Support Level | $0.66 | $3.51 |
| Resistance Level | $0.86 | $6.47 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 42.26 | 25.94 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
About DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.